Illumina, Inc. (NASDAQ:ILMN) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday.
A number of other equities analysts also recently issued reports on ILMN. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target for the company in a report on Tuesday, April 4th. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price target for the company in a report on Tuesday, April 4th. Leerink Swann reaffirmed a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. TheStreet raised Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. Finally, Bank of America Corporation upped their price target on Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Illumina currently has an average rating of “Hold” and an average price target of $174.38.
Shares of Illumina (ILMN) traded up 0.23% on Tuesday, reaching $198.31. The company’s stock had a trading volume of 1,603,560 shares. The company has a market cap of $28.95 billion, a PE ratio of 40.14 and a beta of 0.83. Illumina has a 52-week low of $119.37 and a 52-week high of $198.57. The firm has a 50 day moving average of $174.66 and a 200 day moving average of $171.89.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 20.39% and a net margin of 30.27%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 earnings per share. Analysts predict that Illumina will post $3.63 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/03/illumina-inc-nasdaqilmn-upgraded-to-sell-by-bidaskclub.html.
In other news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total transaction of $3,682,800.00. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at $99,283,868.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the sale, the senior vice president now owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. Insiders sold 123,639 shares of company stock valued at $21,980,677 over the last three months. Corporate insiders own 1.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock valued at $1,056,000 after buying an additional 1,800 shares during the period. State of Tennessee Treasury Department boosted its stake in Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares during the period. Aberdeen Asset Management PLC UK boosted its stake in Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares during the period. Bank of Nova Scotia boosted its stake in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares during the period. Finally, Eastern Bank bought a new stake in Illumina during the first quarter valued at approximately $256,000. Institutional investors and hedge funds own 93.68% of the company’s stock.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
